Fenghai Liu1, Meng Zhao1, Shan Lu1, Liqing Kang1. 1. Department of Magnetic Resonance Imaging, Cangzhou Central Hospital, Cangzhou, Hebei Province, 061001, People's Republic of China.
Abstract
OBJECTIVE: DCE-MRI is an imaging technique that reflects the blood perfusion status of the tissue's microcirculation. The purpose of this article is to explore the clinical value of dynamic contrast-enhanced (DCE)-MRI in distinguishing benign and malignant tongue lesions and the internal heterogeneity of a tumour. METHODS: The patients were divided into a tongue cancer group (22 patients) and a glossitis group (7 patients) based on the pathology results. All of the patients underwent DCE-MRI examination. RESULTS: The results of this study showed that the volume transfer constant (Ktrans), rate constant (Kep), contrast enhancement ratio (CER) and initial area under the gadolinium contrast agent concentration time curve (IAUGG) values of the tongue cancer group were significantly higher than those of the glossitis group, and the difference was statistically significant (P < 0.05). However, the extravascular extracellular volume fraction (Ve), fractional plasma volume (fPV), maximum slope (MaxSlope), and bolus arrival time (BAT) values measured by DCE-MRI in the tongue cancer group were not significantly different from those in the glossitis group (P > 0.05). The results of this study showed that the Ktrans, Kep, and IAUGG values measured by DCE-MRI had a good ability to distinguish tongue inflammation from tumours and Ktrans threshold of 0.484 has the best discriminative ability among them. The mean Ktrans values of stage I-II lesions were significantly higher than that of stage III-IV lesion (p = 0.045). CONCLUSION: DCE-MRI is effective in distinguishing between benign and malignant tongue lesions and the internal heterogeneity of the tumour; it is worth following up in a larger study. CLINICAL REGISTRATION NUMBER: Research registry 6393.
OBJECTIVE: DCE-MRI is an imaging technique that reflects the blood perfusion status of the tissue's microcirculation. The purpose of this article is to explore the clinical value of dynamic contrast-enhanced (DCE)-MRI in distinguishing benign and malignant tongue lesions and the internal heterogeneity of a tumour. METHODS: The patients were divided into a tongue cancer group (22 patients) and a glossitis group (7 patients) based on the pathology results. All of the patients underwent DCE-MRI examination. RESULTS: The results of this study showed that the volume transfer constant (Ktrans), rate constant (Kep), contrast enhancement ratio (CER) and initial area under the gadolinium contrast agent concentration time curve (IAUGG) values of the tongue cancer group were significantly higher than those of the glossitis group, and the difference was statistically significant (P < 0.05). However, the extravascular extracellular volume fraction (Ve), fractional plasma volume (fPV), maximum slope (MaxSlope), and bolus arrival time (BAT) values measured by DCE-MRI in the tongue cancer group were not significantly different from those in the glossitis group (P > 0.05). The results of this study showed that the Ktrans, Kep, and IAUGG values measured by DCE-MRI had a good ability to distinguish tongue inflammation from tumours and Ktrans threshold of 0.484 has the best discriminative ability among them. The mean Ktrans values of stage I-II lesions were significantly higher than that of stage III-IV lesion (p = 0.045). CONCLUSION: DCE-MRI is effective in distinguishing between benign and malignant tongue lesions and the internal heterogeneity of the tumour; it is worth following up in a larger study. CLINICAL REGISTRATION NUMBER: Research registry 6393.
Authors: Per Attner; Juan Du; Anders Näsman; Lalle Hammarstedt; Torbjörn Ramqvist; Johan Lindholm; Linda Marklund; Tina Dalianis; Eva Munck-Wikland Journal: Int J Cancer Date: 2010-10-08 Impact factor: 7.396
Authors: A Dimitrios Colevas; Sue S Yom; David G Pfister; Sharon Spencer; David Adelstein; Douglas Adkins; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; David W Eisele; Moon Fenton; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Debra Leizman; Ellie Maghami; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; James Rocco; Cristina P Rodriguez; Jatin P Shah; Randal S Weber; Matthew Witek; Frank Worden; Weining Zhen; Jennifer L Burns; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2018-05 Impact factor: 11.908
Authors: Per Attner; Juan Du; Anders Näsman; Lalle Hammarstedt; Torbjörn Ramqvist; Johan Lindholm; Linda Marklund; Tina Dalianis; Eva Munck-Wikland Journal: Int J Cancer Date: 2010-06-15 Impact factor: 7.396
Authors: Chong Duan; Jesper F Kallehauge; G Larry Bretthorst; Kari Tanderup; Joseph J H Ackerman; Joel R Garbow Journal: Magn Reson Med Date: 2016-03-04 Impact factor: 4.668
Authors: Gaelen Stanford-Moore; Patrick T Bradshaw; Mark C Weissler; Jose P Zevallos; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Andrew F Olshan Journal: Cancer Causes Control Date: 2018-08-01 Impact factor: 2.506